Brief: Ac Immune Partner Life Molecular Imaging Initiates Phase 3 Study For Alzheimer’S Disease Drug
18/01/2023 13:50
Jan 18 (Reuters) - AC Immune SA ACIU.O :
* AC IMMUNE PARTNER LIFE MOLECULAR IMAGING INITIATES PHASE 3
STUDY
OF TAU PET DIAGNOSTIC PI-2620 FOR ALZHEIMER’S DISEASE
* AC IMMUNE SA - FIRST ALZHEIMER'S PATIENT IMAGED WITH
PI-2620 IN
ADVANCE, PIVOTAL PHASE 3 TRIAL
Source text for Eikon: ID:nGNX8QvQ3p
Further company coverage: ACIU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AC Immune SA
See all newsBrief: Ac Immune To Receive Research Grant From Goradia Family For Development Of Aci-7104 In Parkinson’S Disease
AC Immune Q1 net loss narrows on lower expenses
Brief: AC Immune Announces Amendment To Morphomer ® Tau License And Collaboration Agreement With Lilly
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture